cardiovascular diseases

The Pfizer-BioNTech COVID-19 vaccine has been linked to rare cases of heart inflammation in children and young people. The largest study of these risks in children, published in The Lancet Child & Adolescent Health, concluded that receiving the vaccine is associated with a risk of developing myocarditis or pericarditis within six months of 0.85 additional cases per 100,000 vaccinated children; while after COVID-19 infection, the risk is 2.24 additional cases per 100,000. The study used data from 98% of the British population under the age of 18 (almost 14 million) between January 2020 and December 2022.

Taking melatonin supplements to treat insomnia for more than a year is associated with an increased risk of heart failure—including an increase in hospitalisations and mortality—within five years of use, according to a study presented at a conference of the American Heart Association. The study compared a group of 65,000 adults diagnosed with insomnia who had a prescription for melatonin with another group who did not have a prescription for this supplement.

[The BMJ has retracted this article on 31 March, after having published an "expression of concern" on November 12] A phase 3 clinical trial has analyzed the effectiveness of administering stem cells to prevent heart failure in people who have suffered a major heart attack. The trial included 396 patients, 136 of whom received a stem cell infusion. According to the results, published in The BMJ, the treatment significantly reduced the rates of heart failure, although it did not affect mortality.

An international team has analysed gender representation in more than 1,000 clinical trials on cardiovascular disease between 2017 and 2023, involving more than one million people. Although female participation has increased, especially in areas such as obesity and heart failure, women continue to be underrepresented overall compared to men. The results, presented at the European Society of Cardiology (ESC) Congress held in Madrid from 29 August to 1 September, are published in JAMA Network Open.

A phase III clinical trial involving nearly 34,000 people shows that lowering high blood pressure reduces the risk of dementia and cognitive decline. Participants were aged 40 or older, lived in rural areas of China, and had untreated hypertension. The study results are published in Nature Medicine.

An international team has carried out a review of studies and a meta-analysis on the cardiovascular safety of the drugs used to treat ADHD (attention deficit hyperactivity disorder). Their conclusions are that most of them, and not just the stimulants, affect the pulse and blood pressure. According to the authors, who publish the results in the journal The Lancet Psychiatry, although the changes are slight, ‘professionals should monitor blood pressure and pulse in patients with ADHD treated with any pharmacological intervention’.

An international team has created a tiny temporary pacemaker, smaller than a grain of rice (1.8 mm × 3.5 mm × 1 mm). The device is resorbable by the body, achieves effective pacing in human and various animal cardiac models, and could be implanted less invasively than existing pacemakers, according to a study published in Nature.

Genome analysis of 11,555 individuals revealed 60 genes involved in congenital heart disease, according to a study published today in the journal PNAS. Congenital heart disease is one of the most common birth defects and affects between 1 and 1.8% of live births.

Aspartame, a common sweetener used in many sugar-free foods and drinks, affects the cardiovascular health of mice and monkeys, a study claims. Consuming aspartame increases the animals' insulin levels and contributes to the development of atherosclerosis, the buildup of fatty plaque in the arteries, according to the research article published in Cell Metabolism.

In a group of people at high cardiovascular risk, low to moderate wine consumption was associated with fewer cardiovascular events (cardiovascular death, myocardial infarction, stroke or heart failure), according to a study. The analysis uses urinary concentrations of tartaric acid, a substance found in grapes and grape derivatives, as a biomarker of wine consumption. It finds that consuming between three and 35 glasses per month was associated with fewer cardiovascular events than in people who consumed fewer than three or more than 35 glasses. The study, published in the European Heart Journal, included more than 1,200 participants from Spain's PREDIMED study with an average age of 68 years.